E-Z-EM: AngioDynamics Gets Certifications


November 10, 1997          

PRESS RELEASE
                                       Contact:
                                       Michael P. Cody
FOR IMMEDIATE RELEASE                  Director, Corporate Communications
                                       (518)798-1215, Ext. 140

   ANGIODYNAMICS, INC. RECEIVES ISO 9001 AND EN 46001 CERTIFICATION

Queensbury, NY, November 10. 1997. AngioDynamics, a wholly owned subsidiary of
E-Z-EM, Inc. (Amex: EZM.A and EZM.B) announced today it has received ISO 9001
and EN 46001 quality system certifications by the National Standards Authority
of Ireland.

The achievement of these certifications is an important step in the process of
CE marking the company's products. CE marking is required of all medical devices
sold in Europe after June, 1998. With CE marking, AngioDynamics products can be
freely sold throughout Europe and the regulatory registration process in
non-European markets will be greatly simplified.

Brian Kunst, Vice President of Regulatory Affairs and Quality Assurance said:
"This is an important landmark in the evolution of AngioDynamics into a global
medical device manufacturer. We have designed our internal systems to allow
rapid development of technologically advanced devices and improve operational
efficiency. This will help assure our continued competitiveness in markets
throughout the world."

Eamonn Hobbs, President and CEO commented: "We are very proud that the ISO and
EN certifications have been achieved. This was a major effort on the part of
every employee for the past year. This process made us all realize that
innovative systems and procedures can improve our ability to manage our
resources. This is a long-term management solution for maintaining our design,
manufacturing and quality systems."

The statements made in this press release contain certain forward-looking
statements that involve a number of risks and uncertainties. Actual events or
results may differ from the company's expectations. In addition to matters
described in this release, future actions by the FDA, results of pending or
future clinical trials, as well as the risk factors listed from time to time in
the SEC filings of E-Z-EM, Inc., including but not limited to its Form 1O-Q
for the quarter ended August 30, 1997, as well as its Annual Report on
Form 10-K, may affect the actual results achieved by the Company.


End